Please login to the form below

Not currently logged in
Email:
Password:

Cancer therapy

This page shows the latest Cancer therapy news and features for those working in and with pharma, biotech and healthcare.

Eli Lilly’s Verzenios recommended by NICE as combination therapy for early-stage breast cancer

Eli Lilly’s Verzenios recommended by NICE as combination therapy for early-stage breast cancer

The trial results showed a drop of 32% in cancer recurrence when using Verzenios in combination with endocrine therapy. ... The trial showed that adjuvant treatment using Verzenios in combination with endocrine therapy decreased the risk of breast cancer

Latest news

More from news
Approximately 1 fully matching, plus 490 partially matching documents found.

Latest Intelligence

  • Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy

    Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... targets of small cell lung

  • China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

    There was no robust, regulatory control but that has changed and any cell therapy now has to be properly approved.”. ... Tightening up regulatory policies was vital in order to move on from the cell therapy lowlight that saw a 21-year-old student die

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    Diefenbach said: “The promise of being able to tailor cancer therapy to biology and risk is at the forefront of the drive to discover novel biomarkers. ... The idea of cancer biomarkers is to find one that exists to the exclusion or near-exclusion of

More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.

Latest appointments

  • New hires at Ferring, Flexion and Immunocore New hires at Ferring, Flexion and Immunocore

    It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell

  • Dr Li Zhou joins TxCell as cell engineering VP Dr Li Zhou joins TxCell as cell engineering VP

    transplantation. He joins from ZMKS International Cancer Therapy Biotechnologies, a Chinese immuno-oncology company, where he served as chief scientific officer and director of research and development.

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • Merck appoints ex-Pfizer exec as global head of oncology Merck appoints ex-Pfizer exec as global head of oncology

    lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.

  • Kiadis Pharma appoints Vincent Brichard to supervisory board Kiadis Pharma appoints Vincent Brichard to supervisory board

    protect us from infectious diseases – to recognise and kill cancer cells. ... Atir achieved some extremely compelling clinical data and the phase II study interim analysis in December demonstrated the drug's true potential as an adjunctive life-saving

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • The power of influence in transforming women’s health The power of influence in transforming women’s health

    iii] Lobo R.A. Hormone-replacement therapy: Current thinking. Nat. Rev. Endocrinol. 2017; 13:220–231. ... iv] Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study.

  • World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer

    Ovarian cancer – novel therapeutic approaches. Cancer Therapy Advisor 2017. Available at: https://www.cancertherapyadvisor.com/obstetrics-and-gynecology/ovarian-cancer-novel-therapeutic-approaches/article/617855/. ... Accessed April 2019. 8. Target

  • Creative review: ESMO 2018

    This year’s theme focused on securing access to optimal cancer care – a poignant topic and one that resonates across the healthcare sector, impacting patients in all walks of life. ... Ipsen Group developed an eye-catching attraction to offset this

  • Genetic counsellors: the new healthcare influencers?

    of genes along with less known cancer therapy recommendations. ... to recommend genetic testing to high-risk breast cancer patients, despite the women asking for tests.

  • Successful brands tell stories

    In 2017 Blue Latitude Health was asked to develop differentiated and convincing global messaging for physicians helping prostate cancer patients. ... The therapy was well-established in the more advanced disease stage, but it was still a novelty when

More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....